Surgical Science Sweden AB (publ) (STO: SUS)
Sweden
· Delayed Price · Currency is SEK
161.50
+3.20 (2.02%)
Dec 20, 2024, 5:29 PM CET
STO: SUS Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 859.83 | 882.85 | 802.54 | 366.78 | 104.8 | 101.52 | Upgrade
|
Revenue Growth (YoY) | -5.06% | 10.01% | 118.81% | 249.98% | 3.23% | 54.51% | Upgrade
|
Cost of Revenue | 269.58 | 269.97 | 271.02 | 100.84 | 16.44 | 17.94 | Upgrade
|
Gross Profit | 590.25 | 612.88 | 531.52 | 265.94 | 88.36 | 83.58 | Upgrade
|
Selling, General & Admin | 242.4 | 240.02 | 201.88 | 117.26 | 50.43 | 50.79 | Upgrade
|
Research & Development | 190.7 | 181.57 | 172.79 | 65.71 | 16.57 | 16.95 | Upgrade
|
Other Operating Expenses | 12.17 | - | - | - | - | 0.67 | Upgrade
|
Operating Expenses | 445.27 | 421.59 | 374.66 | 182.97 | 67 | 68.4 | Upgrade
|
Operating Income | 144.98 | 191.29 | 156.86 | 82.98 | 21.37 | 15.18 | Upgrade
|
Interest Expense | - | -0.64 | -0.54 | -0.51 | -0.53 | -0.1 | Upgrade
|
Interest & Investment Income | 14.51 | - | - | - | 0.22 | 0.17 | Upgrade
|
Currency Exchange Gain (Loss) | 12.91 | 12.91 | 5.68 | -6.02 | -1.39 | - | Upgrade
|
Other Non Operating Income (Expenses) | 64.71 | 64.71 | 46.17 | 18.06 | - | - | Upgrade
|
EBT Excluding Unusual Items | 237.11 | 268.26 | 208.17 | 94.5 | 19.66 | 15.25 | Upgrade
|
Merger & Restructuring Charges | - | - | - | -28.7 | - | - | Upgrade
|
Pretax Income | 237.11 | 268.26 | 208.17 | 65.8 | 19.66 | 15.25 | Upgrade
|
Income Tax Expense | 43.77 | 34.29 | 20.2 | -20.44 | 4.05 | 2.65 | Upgrade
|
Net Income to Company | - | 233.97 | 187.97 | 86.25 | 15.61 | 12.6 | Upgrade
|
Net Income | 193.34 | 233.97 | 187.97 | 86.25 | 15.61 | 12.6 | Upgrade
|
Net Income to Common | 193.34 | 233.97 | 187.97 | 86.25 | 15.61 | 12.6 | Upgrade
|
Net Income Growth | -23.44% | 24.47% | 117.95% | 452.66% | 23.88% | - | Upgrade
|
Shares Outstanding (Basic) | 51 | 51 | 51 | 42 | 34 | 28 | Upgrade
|
Shares Outstanding (Diluted) | 51 | 51 | 51 | 43 | 34 | 29 | Upgrade
|
Shares Change (YoY) | 0.26% | 0.05% | 19.32% | 24.15% | 18.32% | 19.45% | Upgrade
|
EPS (Basic) | 3.79 | 4.59 | 3.70 | 2.03 | 0.45 | 0.45 | Upgrade
|
EPS (Diluted) | 3.79 | 4.59 | 3.69 | 2.02 | 0.45 | 0.43 | Upgrade
|
EPS Growth | -23.64% | 24.39% | 82.67% | 348.89% | 4.65% | - | Upgrade
|
Free Cash Flow | 111.07 | 227.84 | 120.14 | 35.21 | 22.83 | 54.88 | Upgrade
|
Free Cash Flow Per Share | 2.18 | 4.47 | 2.36 | 0.83 | 0.66 | 1.89 | Upgrade
|
Gross Margin | 68.65% | 69.42% | 66.23% | 72.51% | 84.32% | 82.33% | Upgrade
|
Operating Margin | 16.86% | 21.67% | 19.54% | 22.62% | 20.39% | 14.95% | Upgrade
|
Profit Margin | 22.49% | 26.50% | 23.42% | 23.52% | 14.89% | 12.41% | Upgrade
|
Free Cash Flow Margin | 12.92% | 25.81% | 14.97% | 9.60% | 21.78% | 54.06% | Upgrade
|
EBITDA | 171.28 | 214.29 | 177.47 | 99 | 27.8 | 19.42 | Upgrade
|
EBITDA Margin | 19.92% | 24.27% | 22.11% | 26.99% | 26.53% | 19.13% | Upgrade
|
D&A For EBITDA | 26.31 | 23 | 20.61 | 16.02 | 6.43 | 4.24 | Upgrade
|
EBIT | 144.98 | 191.29 | 156.86 | 82.98 | 21.37 | 15.18 | Upgrade
|
EBIT Margin | 16.86% | 21.67% | 19.54% | 22.62% | 20.39% | 14.95% | Upgrade
|
Effective Tax Rate | 18.46% | 12.78% | 9.70% | - | 20.62% | 17.38% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.